寶馨科技(002514.SZ):控股股東擬增加對公司提供無息借款、由不超1億元增至不超10億元
格隆匯8月20日丨寶馨科技(002514.SZ)公佈,控股股東江蘇捷登擬增加對公司提供借款,由提供不超過人民幣1億元的無息借款增加至提供不超過人民幣10億元的無息借款,借款額度有效期限為本事項股東大會審議通過之日起至公司2022年度股東大會召開之日止,額度在有效期內可循環滾動使用。實際借款金額及借款期限以雙方簽訂的協議為準。
借款用途主要為滿足公司新能源產業、智能裝備製造的經營發展及公司日常經營所需流動資金,公司無需為上述借款提供抵押或擔保。還款資金來源為公司自有或自籌資金。此次新增的借款額度生效前,公司前期已審議的借款額度仍有效。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.